Goldman Sachs’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $26.5M | Buy |
1,890,246
+786,833
| +71% | +$11M | ﹤0.01% | 1576 |
|
|
2025
Q1 | $17.3M | Sell |
1,103,413
-202,754
| -16% | -$3.17M | ﹤0.01% | 1805 |
|
|
2024
Q4 | $18.2M | Sell |
1,306,167
-283,715
| -18% | -$3.95M | ﹤0.01% | 1849 |
|
|
2024
Q3 | $14.8M | Buy |
1,589,882
+782,548
| +97% | +$7.28M | ﹤0.01% | 1947 |
|
|
2024
Q2 | $7.51M | Buy |
807,334
+810
| +0.1% | +$7.53K | ﹤0.01% | 2325 |
|
|
2024
Q1 | $7.99M | Buy |
806,524
+73,522
| +10% | +$729K | ﹤0.01% | 2231 |
|
|
2023
Q4 | $2.37M | Buy |
733,002
+399,992
| +120% | +$1.29M | ﹤0.01% | 3097 |
|
|
2023
Q3 | $1.77M | Sell |
333,010
-361,311
| -52% | -$1.92M | ﹤0.01% | 3167 |
|
|
2023
Q2 | $6.62M | Buy |
694,321
+447,345
| +181% | +$4.26M | ﹤0.01% | 2362 |
|
|
2023
Q1 | $2.72M | Sell |
246,976
-32,689
| -12% | -$360K | ﹤0.01% | 2991 |
|
|
2022
Q4 | $4.14M | Buy |
279,665
+96,368
| +53% | +$1.43M | ﹤0.01% | 2762 |
|
|
2022
Q3 | $3.5M | Buy |
183,297
+87,119
| +91% | +$1.66M | ﹤0.01% | 2933 |
|
|
2022
Q2 | $2.05M | Buy |
96,178
+33,605
| +54% | +$716K | ﹤0.01% | 3428 |
|
|
2022
Q1 | $1.21M | Buy |
62,573
+14,339
| +30% | +$276K | ﹤0.01% | 3969 |
|
|
2021
Q4 | $1M | Buy |
48,234
+7,607
| +19% | +$158K | ﹤0.01% | 4023 |
|
|
2021
Q3 | $971K | Buy |
40,627
+8,868
| +28% | +$212K | ﹤0.01% | 3998 |
|
|
2021
Q2 | $866K | Buy |
31,759
+10,362
| +48% | +$283K | ﹤0.01% | 4111 |
|
|
2021
Q1 | $619K | Sell |
21,397
-203,368
| -90% | -$5.88M | ﹤0.01% | 4220 |
|
|
2020
Q4 | $6.32M | Buy |
224,765
+45,389
| +25% | +$1.28M | ﹤0.01% | 2343 |
|
|
2020
Q3 | $5.26M | Buy |
179,376
+7,462
| +4% | +$219K | ﹤0.01% | 2346 |
|
|
2020
Q2 | $5.2M | Sell |
171,914
-27,716
| -14% | -$838K | ﹤0.01% | 2322 |
|
|
2020
Q1 | $5.95M | Buy |
+199,630
| New | +$5.95M | ﹤0.01% | 2134 |
|